- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Silver Spring Today
By the People, for the People
United Therapeutics Announces Successful Tyvaso Trial
Pivotal TETON-1 study meets primary endpoint for treating pulmonary hypertension.
Mar. 30, 2026 at 6:08pm
Got story updates? Submit your updates here. ›
United Therapeutics Corporation, a public benefit pharmaceutical company, announced that its pivotal TETON-1 study of the drug Tyvaso has met its primary endpoint for the treatment of pulmonary hypertension. The successful trial results mark a significant milestone for the company's efforts to expand the approved uses of Tyvaso, an inhaled therapy for certain types of pulmonary hypertension.
Why it matters
Pulmonary hypertension is a chronic and debilitating condition that can severely impact a patient's quality of life. The positive TETON-1 results indicate Tyvaso could become an important new treatment option for those suffering from this disease, providing hope for improved outcomes and symptom management.
The details
The TETON-1 study evaluated the safety and efficacy of Tyvaso in treating pulmonary hypertension. The trial's primary endpoint, which was met, measured improvements in exercise capacity as assessed by the six-minute walk test. United Therapeutics plans to use these results to support regulatory submissions seeking to expand Tyvaso's approved indications.
- The TETON-1 pivotal study was conducted throughout 2025.
- United Therapeutics announced the successful trial results on March 30, 2026.
The players
United Therapeutics Corporation
A public benefit pharmaceutical company that develops therapies for pulmonary hypertension and other rare diseases.
Tyvaso
An inhaled therapy developed by United Therapeutics for the treatment of certain types of pulmonary hypertension.
What’s next
United Therapeutics plans to use the TETON-1 results to support regulatory submissions seeking to expand Tyvaso's approved indications for the treatment of pulmonary hypertension.
The takeaway
The successful TETON-1 trial of United Therapeutics' Tyvaso represents an important advancement in the treatment of pulmonary hypertension, a debilitating condition that impacts many patients. If approved for expanded use, Tyvaso could provide a new therapeutic option to improve quality of life and clinical outcomes for those suffering from this serious disease.
